Xilio Therapeutics Inc [XLO] stock prices are up 2.76% to $0.7 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The XLO shares have gain 6.94% over the last week, with a monthly amount drifted -6.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xilio Therapeutics Inc [NASDAQ: XLO] stock has seen the most recent analyst activity on August 06, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $2. Previously, Chardan Capital Markets started tracking the stock with Buy rating on December 21, 2022, and set its price target to $7. On January 10, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $36 on the stock. Raymond James started tracking the stock assigning an Outperform rating and suggested a price target of $31 on November 16, 2021. Morgan Stanley initiated its recommendation with an Overweight and recommended $32 as its price target on November 16, 2021. Guggenheim started tracking with a Buy rating for this stock on November 16, 2021, and assigned it a price target of $40. In a note dated November 16, 2021, Cowen initiated an Outperform rating.
The stock price of Xilio Therapeutics Inc [XLO] has been fluctuating between $0.62 and $1.70 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Xilio Therapeutics Inc [NASDAQ: XLO] shares were valued at $0.7 at the most recent close of the market. An investor can expect a potential return of 900.0% based on the average XLO price forecast.
Analyzing the XLO fundamentals
The Xilio Therapeutics Inc [NASDAQ:XLO] reported sales of 31.80M for trailing twelve months, representing a surge of 742.51%. Gross Profit Margin for this corporation currently stands at 0.4% with Operating Profit Margin at -1.38%, Pretax Profit Margin comes in at -1.33%, and Net Profit Margin reading is -1.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -6.19 and Total Capital is -0.57. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6748 points at the first support level, and at 0.6546 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7157, and for the 2nd resistance point, it is at 0.7364.
Ratios To Look Out For
It’s worth pointing out that Xilio Therapeutics Inc [NASDAQ:XLO]’s Current Ratio is 2.20. On the other hand, the Quick Ratio is 2.20, and the Cash Ratio is 1.84. Considering the valuation of this stock, the price to sales ratio is 1.15.
Transactions by insiders
Recent insider trading involved Shannon James Samuel, Director, that happened on Jun 16 ’25 when 45000.0 shares were purchased. Director, Shannon James Samuel completed a deal on Jun 17 ’25 to buy 25000.0 shares. Meanwhile, PRESIDENT AND CEO Russo Rene bought 36289.0 shares on Jun 16 ’25.
